Modeling the effects of drug resistant influenza virus in a pandemic

Virology Journal

Volumn 5, Issue , 2008, Pages

  Brockmann, Stefan O ^a   Schwehm, Markus ^b   Duerr, Hans Peter ^b   Witschi, Mark ^c   Koch, Daniel ^c   Vidondo, Beatriz ^c   Eichner, Martin ^b  

^a Baden Wurttemberg State Health Office   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c FEDERAL OFFICE OF PUBLIC HEALTH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

OSELTAMIVIR; SIALIDASE INHIBITOR; ANTIVIRUS AGENT; ENZYME INHIBITOR; SIALIDASE; VIRUS PROTEIN;

ARTICLE; DISEASE SIMULATION; HOSPITALIZATION; HUMAN; INFLUENZA; INFLUENZA VIRUS; MATHEMATICAL MODEL; OUTPATIENT; PANDEMIC; PROGNOSIS; SEASONAL VARIATION; VIRUS RESISTANCE; VIRUS TRANSMISSION; ANTIVIRAL RESISTANCE; BIOLOGICAL MODEL; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; EPIDEMIC; METABOLISM; ORTHOMYXOVIRUS; VIROLOGY;

ORTHOMYXOVIRIDAE;

ANTIVIRAL AGENTS; DISEASE OUTBREAKS; DRUG RESISTANCE, VIRAL; ENZYME INHIBITORS; HOSPITALIZATION; HUMANS; INFLUENZA, HUMAN; MODELS, BIOLOGICAL; NEURAMINIDASE; ORTHOMYXOVIRIDAE; OUTPATIENTS; VIRAL PROTEINS;

EID: 57049157697     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-5-133     Document Type: Article

References (23)

1. Strengthening pandemic-influenza preparedness and response, including application of the International Health Regulations (2005). Fifty-ninth World Health Assembly. WHO document A59/4. http://www.who.int/gb/ebwha/pdf_files/ WHA59/A59_4-en.pdf
2. Updated review of influenza antiviral medicinal products for potential use during pandemic by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA). http://www.emea.europa.eu/htms/human/ pandemicinfluenza/antivirals.htm
3. Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. AS Monto JL McKimm-Breschkin C Macken AW Hampson A Hay A Klimov M Tashiro RG Webster M Aymard FG Hayden M Zambon, Antimicrob Agents Chemother 2006 50 2395 2402 16801417 10.1128/AAC.01339-05
4. Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets. ML Herlocher R Truscon S Elias HL Yen NA Roberts SE Ohmit AS Monto, J Infect Dis 2004 190 1627 1630 10.1086/424572 15478068
5. Emergence of drug resistance during an influenza epidemic: insights from a mathematical model. NI Stilianakis AS Perelson FG Hayden, J Infect Dis 1998 177 863 873 9534957
6. Interim ECDC Risk Assessment - Emergence of seasonal influenza viruses type A/H1N1 with oseltamivir resistance in some European Countries at the start of the 2007-8 influenza season. http://www.ecdc.europa.eu/pdf/080127_os.pdf
7. Emergence of resistance to oseltamivir among influenza A(H1N1) viruses in Europe. A Lackenby O Hungnes SG Dudman A Meijer WJ Paget AJ Hay MC Zambon, Euro Surveill 2008 13 5
8. Update A(H1N1) viruses resistant to oseltamivir. http://www.eiss.org/ html/lb_h1n1_resistance_oseltamivir.html
9. Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic. P Ward I Small J Smith P Suter R Dutkowski, J Antimicrob Chemother 2005 55 Suppl 1 i5 i21 10.1093/jac/dki018 15709056
10. Oral oseltamivir treatment of influenza in children. RJ Whitley FG Hayden KS Reisinger N Young R Dutkowski D Ipe RG Mills P Ward, Pediatr Infect Dis J 2001 20 127 133 10.1097/00006454-200102000-00002 11224828
11. Influenza virus susceptibility and resistance to oseltamivir. FY Aoki G Boivin N Roberts, Antivir Ther 2007 12 603 616 17944268
12. The estimation of the basic reproduction number for infectious diseases. K Dietz, Stat Methods Med Res 1993 2 23 41 10.1177/096228029300200103 8261248
13. The influenza pandemic preparedness planning tool InfluSim. M Eichner M Schwehm HP Duerr SO Brockmann, BMC Infect Dis 2007 7 17 17355639 10.1186/1471-2334-7-17
14. Influenza pandemic intervention planning using InfluSim: pharmaceutical and non-pharmaceutical interventions. HP Duerr SO Brockmann I Piechotowski M Schwehm M Eichner, BMC Infect Dis 2007 7 76 17629919 10.1186/1471-2334-7-76
15. Interventions for the interruption or reduction of the spread of respiratory viruses. T Jefferson R Foxlee C Del Mar L Dooley E Ferroni B Hewak A Prabhala S Nair A Rivetti, Cochrane Database Syst Rev 2007 CD006207 17943895
16. Professional and home-made face masks reduce exposure to respiratory infections among the general population. M van der Sande P Teunis R Sabel, PLoS ONE 2008 3 e2618 18612429 10.1371/journal.pone.0002618
17. Comparative estimation of the reproduction number for pandemic influenza from daily case notification data. G Chowell H Nishiura LM Bettencourt, J R Soc Interface 2007 4 155 166 17254982 10.1098/rsif.2006.0161
18. Strategies for containing an emerging influenza pandemic in Southeast Asia. NM Ferguson DA Cummings S Cauchemez C Fraser S Riley A Meeyai S Iamsirithaworn DS Burke, Nature 2005 437 209 214 10.1038/nature04017 16079797
19. Containing pandemic influenza with antiviral agents. IM Longini Jr ME Halloran A Nizam Y Yang, Am J Epidemiol 2004 159 623 633 10.1093/aje/kwh092 15033640
20. A population-dynamic model for evaluating the potential spread of drug-resistant influenza virus infections during community-based use of antivirals. NM Ferguson S Mallett H Jackson N Roberts P Ward, J Antimicrob Chemother 2003 51 977 990 10.1093/jac/dkg136 12654752
21. Emergence of drug-resistant influenza virus: population dynamical considerations. RR Regoes S Bonhoeffer, Science 2006 312 389 391 10.1126/science.1122947 16627735
22. Modelling the impact of an influenza pandemic on critical care services in England. DK Menon BL Taylor SA Ridley, Anaesthesia 2005 60 952 954 10.1111/j.1365-2044.2005.04372.x 16179037
23. The expected number of hospitalisations and beds needed due to pandemic influenza on a regional level in the Netherlands. ML van Genugten ML Heijnen, Virus Res 2004 103 17 23 10.1016/j.virusres.2004.02.007 15163483